PepGen Inc. (PEPG)
NASDAQ: PEPGHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PEPG stock chart
Technical analysisKey statistics
All statistics- Market cap
- $356.31M
- EPS (TTM)
- -$0.77
- Dividend yield
- None
- 52-week range
- 1.31 – 7.80
- Day range
- 3.69 – 3.98
- Volume / Avg
- 4.43M / 3.26M
- Beta
- —
- Shares outstanding
- 94.26M
52-week range
PEPG stock today
On Nov 20, PEPG ended the session at $3.78, shedding $0.15 (3.82%), versus the S&P 500's 3.70% decline. At this level, PEPG sits in the middle of its 52-week range of $1.31 to $7.80: 51.5% below the high, set on Jan 2, 2026 and 188.5% above the low. PEPG is down 41.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 32.0%.
PepGen has posted a net loss over the last twelve months (EPS of -$0.77), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About PepGen
Company profilePepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. James G. McArthur Ph.D.
- Headquarters
- Boston, MA
- Employees
- 53
- IPO year
- 2022
- Website
- pepgen.com
Financial highlights
Full financialsPepGen reported a net loss of $89.7 million, compared with a loss of $90.0 million a year earlier. Diluted earnings per share came in at -$2.12.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-89.66M | $-89.98M | $-78.63M | $-69.10M | $-27.28M |
| EPS (diluted) | $-2.12 | $-2.85 | $-3.30 | $-4.42 | $-30.27 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$13.75+263.76%
- Strong buy 0
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.28 vs $-0.27
- Surprise
- -3.70%
PEPG news
All PEPG newsPepGen peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ASPEAspen Neuroscience Inc. | 12.42 | +0.24% | $361.16M | vs PEPG |
| PBYIPuma Biotechnology Inc | 7.05 | -0.98% | $364.47M | vs PEPG |
| CTNMContineum Therapeutics Inc. Class A | 8.68 | -3.98% | $340.83M | vs PEPG |
| PHATPhathom Pharmaceuticals Inc. | 4.66 | -8.27% | $378.82M | vs PEPG |
| MPLTMapLight Therapeutics Inc. | 5.94 | -7.48% | $330.12M | vs PEPG |
| INOInovio Pharmaceuticals Inc. | 1.76 | +2.92% | $329.66M | vs PEPG |
| LRMRLarimar Therapeutics Inc. | 3.14 | -2.48% | $328.55M | vs PEPG |
| IRDOpus Genetics Inc. | 3.99 | -2.21% | $385.65M | vs PEPG |
Indexes, lists and sector
PepGen stock FAQ
What is PepGen's stock price today?
PEPG last traded at $3.78 as of Nov 20, 4:00 PM EST, down 3.82% on the day. Prices are delayed at least 15 minutes.
Who is PepGen's CEO?
Dr. James G. McArthur Ph.D. is the chief executive officer of PepGen Inc., which has about 53 employees.
What is the PEPG 52-week high?
The 52-week high for PEPG is $7.80 and the 52-week low is $1.31. The stock is currently 51.5% below its high.